Pharmacogenetic testing in oncology: a Brazilian perspective
Pharmacogenetics, a major component of individualized or precision medicine, relies on human genetic diversity. The remarkable developments in sequencing technologies have revealed that the number of genetic variants modulating drug action is much higher than previously thought and that a true perso...
Main Author: | Guilherme Suarez-Kurtz |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier España
2018-10-01
|
Series: | Clinics |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322018000200330&lng=en&tlng=en |
Similar Items
-
Pharmacogenomic tests of oncology drugs at Instituto Nacional de Câncer (INCA)
by: Guilherme Suarez-Kurtz
Published: (2021-10-01) -
Pharmacogenomic tests in Oncology - finding the right dose
by: Jeziel Basso, et al.
Published: (2021-10-01) -
Genotyping of <i>UGT1A1</i> and <i>DPYD</i> polymorphisms in patients with colorectal cancer. A review
by: Natalia N. Timoshkina, et al.
Published: (2023-12-01) -
TPMT and NUDT15 testing for thiopurine therapy: A major tertiary hospital experience and lessons learned
by: Liuh Ling Goh, et al.
Published: (2022-09-01) -
A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening
by: Chi C. Tong, et al.
Published: (2018-07-01)